bpc 157 and tirzepatide BPC-157 Tirzepatide BPC-157 B6 | Advanced

Consult a licensed medical provider before starting any peptide protocol

Visible body composition changes from the combination usually become apparent at weeks 6-8, when AOD 9604 has been active for 2-4 weeks alongside escalating tirzepatide doses

2014 Feb;149(1):153-5

This helps maintain the treatment regimen that is essential for their health

The agency flagged three adverse events in its FAERS database tied to compounded injectable BPC-157, including a case in which a patient developed diffuse hyperpigmentation and gingival darkening after using a blended BPC-157/TB-500 product labeled "research purposes only." The safety concern most specific to BPC-157 is its mechanism of action

A consultation is required to assess candidacy and determine the appropriate protocol